论文部分内容阅读
应用中国预防医学科学院流行病学微生物学研究所出血热室研制生产的HFRS病毒鸡胚细胞灭活疫苗，连续2年在贵州省HFRS高发病区的遵义县进行了较大范围的人群免疫接种，并对其效果进行了观察。疫苗经1992年40966人初次免疫和1993年32556人加强免疫，除注射时先后有5人出现景厥、注射后少数人出现低热、注射部位短时轻微疼痛外，未见其他不适反应，说明疫苗的安全性是可靠的。初次免疫后血清NT抗体阳转率40．54％，加强免疫后血清NT抗体阳性率达75％以上，提示疫苗的免疫原性值得肯定。在疫苗免疫后的第1个观察年度内，疫苗组发病率9．76／10万，较对照组57．77／10万明显偏低（X2＝15．5，P＜0．01），保护率为83．11％；1年后加强免疫人群发病率9．21／10万，亦明显低于对照组发病率188．22／10万（X2＝53．88，P＜0．01），保护率达95．10％，疫苗起到了较好的保护作用，具有明显的流行病学效果。研究结果表明，该疫苗是安全的，可以较好地诱导机体产生NT抗体，有良好的流行病学效果，能有效地控制HFRS的流行。
The HFRS virus chick embryo cell inactivated vaccine developed and produced by the Institute of Epidemiology and Microbiology, Chinese Academy of Preventive Medicine, was used to immunize a large population in Zunyi County, a high prevalence area of HFRS in Guizhou Province, for 2 consecutive years. And its effect was observed. The vaccine was first immunized by 40,966 people in 1992 and 32,556 people were boosted in 1993. There were 5 people who had Jingjue injection after injection and a few people showed low fever after injection and no minor discomfort at the injection site. The safety is reliable. After the first immunization, the serum NT antibody positive rate was 40.54%. After the boost, the positive rate of serum NT antibody was over 75%, which indicated that the immunogenicity of the vaccine was worthy of recognition. In the first observation year after vaccine immunization, the incidence of vaccine group was 9.76 / 100 000, significantly lower than 57.77 / 100 000 in control group (X2 = 15.5, P <0.01). The protection rate Was 83.11%. After one year, the incidence of intensive immunization was 9.21 / 100000, which was significantly lower than that of the control group (188.22 / 100000) (X2 = 53.88, P <0.01) The rate of 95.10%, the vaccine played a good protective effect, with significant epidemiological effects. The results show that the vaccine is safe, can induce the body to produce NT antibodies, have good epidemiological effects, can effectively control the epidemic of HFRS.